iX Biopharma also registered revenue growth in its specialty pharmaceuticals segment, mainly contributed by medicinal cannabis product sales and services. However, its nutraceuticals segment saw lower revenue y-o-y due to supply chain and logistics disruptions in Australia and China as a result of Covid-19.
Specialty pharmaceutical company iX Biopharma has reported revenue of $14.4 million for the FY2022 ended June, an eight-fold, or 725% increase from its FY2021 revenue of $1.7 million.
The revenue surge was mainly driven by the upfront payment received from the group’s Wafermine out-licensing deal with Seelos Therapeutics, Inc. in November 2021.
![[19/05/26] new top stories](/_next/image?url=https%3A%2F%2Fedgemarkets-transferred.s3-ap-southeast-1.amazonaws.com%2FPEO_KUNHEE_PARK_01_AC_2.jpg%3FTd3bG7fJqxPW3hMZRxhyfGgI25yRRD5v&w=640&q=75)
